Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

Дата публикации: 17-02-2026 12:00:00

Exdensur is the first and only ultra-long-acting biologic in the EU to treat respiratory diseases

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps07.4106-01-2026
2Depemokimab receives positive CHMP opinion for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps012.8412-12-2025
3Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps 011.0415-12-2025
4Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)08.9308-04-2026
5Exdensur (depemokimab) approved in China for the treatment of severe asthma 06.7730-03-2026
6Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma 09.2516-12-2025
7Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD)08.2606-02-2026
8Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease (COPD)08.7112-12-2025
9Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD)06.105-01-2026
10Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B014.3927-03-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.24. Источник: www.gsk.com.